SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Esteban E) "

Sökning: WFRF:(Esteban E)

  • Resultat 1-10 av 150
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Thomas, HS, et al. (författare)
  • 2019
  • swepub:Mat__t
  •  
2.
  • Glasbey, JC, et al. (författare)
  • 2021
  • swepub:Mat__t
  •  
3.
  • 2021
  • swepub:Mat__t
  •  
4.
  •  
5.
  •  
6.
  • Ruilope, LM, et al. (författare)
  • Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial
  • 2019
  • Ingår i: American journal of nephrology. - : S. Karger AG. - 1421-9670 .- 0250-8095. ; 50:5, s. 345-356
  • Tidskriftsartikel (refereegranskat)abstract
    • <b><i>Background:</i></b> Among people with diabetes, those with kidney disease have exceptionally high rates of cardiovascular (CV) morbidity and mortality and progression of their underlying kidney disease. Finerenone is a novel, nonsteroidal, selective mineralocorticoid receptor antagonist that has shown to reduce albuminuria in type 2 diabetes (T2D) patients with chronic kidney disease (CKD) while revealing only a low risk of hyperkalemia. However, the effect of finerenone on CV and renal outcomes has not yet been investigated in long-term trials. <b><i>Patients and</i></b> <b><i>Methods:</i></b> The Finerenone in Reducing CV Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) trial aims to assess the efficacy and safety of finerenone compared to placebo at reducing clinically important CV and renal outcomes in T2D patients with CKD. FIGARO-DKD is a randomized, double-blind, placebo-controlled, parallel-group, event-driven trial running in 47 countries with an expected duration of approximately 6 years. FIGARO-DKD randomized 7,437 patients with an estimated glomerular filtration rate ≥25 mL/min/1.73 m<sup>2</sup> and albuminuria (urinary albumin-to-creatinine ratio ≥30 to ≤5,000 mg/g). The study has at least 90% power to detect a 20% reduction in the risk of the primary outcome (overall two-sided significance level α = 0.05), the composite of time to first occurrence of CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure. <b><i>Conclusions:</i></b> FIGARO-DKD will determine whether an optimally treated cohort of T2D patients with CKD at high risk of CV and renal events will experience cardiorenal benefits with the addition of finerenone to their treatment regimen. Trial Registration: EudraCT number: 2015-000950-39; ClinicalTrials.gov identifier: NCT02545049.
  •  
7.
  •  
8.
  •  
9.
  • 2019
  • Tidskriftsartikel (refereegranskat)
  •  
10.
  • Buchanan, E. M., et al. (författare)
  • The Psychological Science Accelerator's COVID-19 rapid-response dataset
  • 2023
  • Ingår i: Scientific Data. - : Springer Science and Business Media LLC. - 2052-4463. ; 10:1
  • Tidskriftsartikel (refereegranskat)abstract
    • In response to the COVID-19 pandemic, the Psychological Science Accelerator coordinated three large-scale psychological studies to examine the effects of loss-gain framing, cognitive reappraisals, and autonomy framing manipulations on behavioral intentions and affective measures. The data collected (April to October 2020) included specific measures for each experimental study, a general questionnaire examining health prevention behaviors and COVID-19 experience, geographical and cultural context characterization, and demographic information for each participant. Each participant started the study with the same general questions and then was randomized to complete either one longer experiment or two shorter experiments. Data were provided by 73,223 participants with varying completion rates. Participants completed the survey from 111 geopolitical regions in 44 unique languages/dialects. The anonymized dataset described here is provided in both raw and processed formats to facilitate re-use and further analyses. The dataset offers secondary analytic opportunities to explore coping, framing, and self-determination across a diverse, global sample obtained at the onset of the COVID-19 pandemic, which can be merged with other time-sampled or geographic data.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 150
Typ av publikation
tidskriftsartikel (136)
forskningsöversikt (8)
konferensbidrag (2)
annan publikation (1)
Typ av innehåll
refereegranskat (139)
övrigt vetenskapligt/konstnärligt (8)
Författare/redaktör
Randich, S. (28)
Smiljanic, R. (28)
Gilmore, G. (27)
Zaggia, S. (26)
Jofré, P. (25)
Bragaglia, A. (25)
visa fler...
Tautvaisiene, G. (24)
Morbidelli, L. (24)
Magrini, L. (24)
Franciosini, E. (23)
Hourihane, A. (23)
Bensby, T. (22)
Pancino, E. (22)
Carraro, G. (18)
Bayo, A. (17)
Castano, A (17)
Kolossa-Gehring, M (17)
Vallenari, A. (16)
Prisinzano, L. (15)
Knudsen, LE (15)
Spina, L. (14)
Damiani, F. (14)
Gonneau, A. (14)
Schoeters, G (14)
Den Hond, E (14)
Francois, P (14)
Esteban, M (13)
Bergemann, M. (13)
Monaco, L (13)
Jeffries, R. D. (13)
Drazdauskas, A. (13)
Flaccomio, E. (13)
Lewis, J (12)
Costado, M. T. (12)
Sacco, G. G. (12)
Koch, HM (12)
Horvat, M (12)
Rudnai, P (12)
Ligocka, D (12)
Tratnik, JS (12)
Worley, C. C. (12)
Gutleb, AC (12)
Sousa, S.G. (11)
Korn, Andreas, 1972- (11)
Van der Swaelmen, M. (11)
Worley, C. (11)
Masseron, T. (11)
Biot, P (11)
Sepai, O (11)
Mazej, D (11)
visa färre...
Lärosäte
Karolinska Institutet (63)
Lunds universitet (38)
Uppsala universitet (36)
Linköpings universitet (15)
Umeå universitet (9)
Stockholms universitet (9)
visa fler...
Göteborgs universitet (8)
Chalmers tekniska högskola (7)
Sveriges Lantbruksuniversitet (6)
Kungliga Tekniska Högskolan (3)
Malmö universitet (2)
Linnéuniversitetet (2)
Luleå tekniska universitet (1)
Mittuniversitetet (1)
Naturhistoriska riksmuseet (1)
visa färre...
Språk
Engelska (150)
Forskningsämne (UKÄ/SCB)
Naturvetenskap (64)
Medicin och hälsovetenskap (41)
Samhällsvetenskap (7)
Teknik (5)
Lantbruksvetenskap (3)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy